These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 21038076)

  • 1. Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients.
    Berge M; Guillemain R; Trégouet DA; Amrein C; Boussaud V; Chevalier P; Lillo-Lelouet A; Le Beller C; Laurent-Puig P; Beaune PH; Billaud EM; Loriot MA
    Eur J Clin Pharmacol; 2011 Mar; 67(3):253-60. PubMed ID: 21038076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
    Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
    Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.
    Scholz I; Oberwittler H; Riedel KD; Burhenne J; Weiss J; Haefeli WE; Mikus G
    Br J Clin Pharmacol; 2009 Dec; 68(6):906-15. PubMed ID: 20002085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
    Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
    Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction.
    Moriyama B; Falade-Nwulia O; Leung J; Penzak SR; JJingo C; Huang X; Henning SA; Wilson WH; Walsh TJ
    Mycoses; 2011 Nov; 54(6):e877-9. PubMed ID: 21615537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.
    Thomas A; Korb V; Guillemain R; Caruba T; Boussaud V; Billaud E; Prognon P; Begué D; Sabatier B
    J Clin Pharm Ther; 2010 Feb; 35(1):49-53. PubMed ID: 20175811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.
    Driscoll TA; Yu LC; Frangoul H; Krance RA; Nemecek E; Blumer J; Arrieta A; Graham ML; Bradfield SM; Baruch A; Liu P
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5770-9. PubMed ID: 21968355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults.
    Driscoll TA; Frangoul H; Nemecek ER; Murphey DK; Yu LC; Blumer J; Krance RA; Baruch A; Liu P
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5780-9. PubMed ID: 21911570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.
    Weiss J; Ten Hoevel MM; Burhenne J; Walter-Sack I; Hoffmann MM; Rengelshausen J; Haefeli WE; Mikus G
    J Clin Pharmacol; 2009 Feb; 49(2):196-204. PubMed ID: 19033450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience.
    Racil Z; Winterova J; Kouba M; Zak P; Malaskova L; Buresova L; Toskova M; Lengerova M; Kocmanova I; Weinbergerova B; Timilsina S; Rolencova M; Cetkovsky P; Mayer J
    Mycoses; 2012 Nov; 55(6):483-92. PubMed ID: 22429709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomics of the triazole antifungal agent voriconazole.
    Mikus G; Scholz IM; Weiss J
    Pharmacogenomics; 2011 Jun; 12(6):861-72. PubMed ID: 21692616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers.
    Wang G; Lei HP; Li Z; Tan ZR; Guo D; Fan L; Chen Y; Hu DL; Wang D; Zhou HH
    Eur J Clin Pharmacol; 2009 Mar; 65(3):281-5. PubMed ID: 18982321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype.
    Zonios D; Yamazaki H; Murayama N; Natarajan V; Palmore T; Childs R; Skinner J; Bennett JE
    J Infect Dis; 2014 Jun; 209(12):1941-8. PubMed ID: 24403552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients.
    Kim SH; Yim DS; Choi SM; Kwon JC; Han S; Lee DG; Park C; Kwon EY; Park SH; Choi JH; Yoo JH
    Int J Infect Dis; 2011 Nov; 15(11):e753-8. PubMed ID: 21831685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring.
    Hassan A; Burhenne J; Riedel KD; Weiss J; Mikus G; Haefeli WE; Czock D
    Ther Drug Monit; 2011 Feb; 33(1):86-93. PubMed ID: 21192313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype.
    Moriyama B; Jarosinski PF; Figg WD; Henning SA; Danner RL; Penzak SR; Wayne AS; Walsh TJ
    Pharmacotherapy; 2013 Mar; 33(3):e19-22. PubMed ID: 23400848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Voriconazole therapeutic drug monitoring: focus on safety.
    Pasqualotto AC; Xavier MO; Andreolla HF; Linden R
    Expert Opin Drug Saf; 2010 Jan; 9(1):125-37. PubMed ID: 20021293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects.
    Andrews E; Damle BD; Fang A; Foster G; Crownover P; LaBadie R; Glue P
    Br J Clin Pharmacol; 2008 Apr; 65(4):531-9. PubMed ID: 18294327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.
    Iwamoto T; Monma F; Fujieda A; Nakatani K; Katayama N; Okuda M
    Clin Ther; 2011 Aug; 33(8):1077-80. PubMed ID: 21802143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics.
    Rengelshausen J; Banfield M; Riedel KD; Burhenne J; Weiss J; Thomsen T; Walter-Sack I; Haefeli WE; Mikus G
    Clin Pharmacol Ther; 2005 Jul; 78(1):25-33. PubMed ID: 16003289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.